FK
FREEMAN KEVIN D Director
Board M
US US · SEC (Form 4)
€168,970
▲ Purchases (20 ops.)
Explore the detailed record of transactions filed by FREEMAN KEVIN D, Director. Officer active across 1 companies, notably Galectin Therapeutics INC. Aggregated, 20 filings have been published. Total volume traded: €169k. The latest transaction was filed on 19 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations 20 total
€6,286 5,000 shares @ €1.2571 0.0044% mcap 3.7% of flow
Common Stock
SEC:0001133416-22-000063:0 · 19 May 2022
Ideal exit: 13 Feb 2023 (T+270) €7,930 5,000 shares @ €1.586 0.0056% mcap 4.7% of flow
Common Stock
SEC:0001133416-22-000057:0 · 18 Apr 2022
Ideal exit: 13 Jan 2023 (T+270) €8,655 5,000 shares @ €1.731 11.2% of flow
Common Stock
SEC:0001133416-22-000008 · 19 Jan 2022
Ideal exit: 16 Oct 2022 (T+270) €8,655 5,000 shares @ €1.731 11.2% of flow
Common Stock
SEC:0001133416-22-000010 · 19 Jan 2022
Ideal exit: 16 Oct 2022 (T+270) €8,655 5,000 shares @ €1.731 0.0061% mcap 5.1% of flow
Common Stock
SEC:0001133416-22-000008:0 · 19 Jan 2022
Ideal exit: 16 Oct 2022 (T+270) €8,655 5,000 shares @ €1.731 0.0061% mcap 5.1% of flow
Common Stock
SEC:0001133416-22-000010:0 · 19 Jan 2022
Ideal exit: 16 Oct 2022 (T+270) €10,123 5,000 shares @ €2.0246 13.1% of flow
Common Stock
SEC:0001133416-21-000027 · 15 Dec 2021
Ideal exit: 11 Sept 2022 (T+270) €10,084 5,000 shares @ €2.0168 13.0% of flow
Common Stock
SEC:0001133416-21-000025 · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) €10,123 5,000 shares @ €2.0246 0.0071% mcap 6.0% of flow
Common Stock
SEC:0001133416-21-000027:0 · 15 Dec 2021
Ideal exit: 11 Sept 2022 (T+270) €10,084 5,000 shares @ €2.0168 0.0071% mcap 6.0% of flow
Common Stock
SEC:0001133416-21-000025:0 · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) €10,350 5,000 shares @ €2.0699 13.4% of flow
Common Stock
SEC:0001133416-21-000023 · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) €10,350 5,000 shares @ €2.0699 0.0072% mcap 6.1% of flow
Common Stock
SEC:0001133416-21-000023:0 · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) €5,426 2,000 shares @ €2.7132 7.0% of flow
Common Stock
SEC:0001133416-21-000017 · 29 Oct 2021
Ideal exit: 26 Jul 2022 (T+270) €5,426 2,000 shares @ €2.7132 0.0038% mcap 3.2% of flow
Common Stock
SEC:0001133416-21-000017:0 · 29 Oct 2021
Ideal exit: 26 Jul 2022 (T+270) €5,488 2,000 shares @ €2.744 7.1% of flow
Common Stock
SEC:0001133416-21-000013 · 21 Oct 2021
Ideal exit: 18 Jul 2022 (T+270) €5,488 2,000 shares @ €2.744 0.0038% mcap 3.2% of flow
Common Stock
SEC:0001133416-21-000013:0 · 21 Oct 2021
Ideal exit: 18 Jul 2022 (T+270) €8,689 3,000 shares @ €2.8962 11.2% of flow
Common Stock
SEC:0001133416-21-000011 · 19 Oct 2021
Ideal exit: 16 Jul 2022 (T+270) €8,689 3,000 shares @ €2.8962 0.0061% mcap 5.1% of flow
Common Stock
SEC:0001133416-21-000011:0 · 19 Oct 2021
Ideal exit: 16 Jul 2022 (T+270) €9,907 3,000 shares @ €3.3023 12.8% of flow
Common Stock
SEC:0001140361-21-032248 · 23 Sept 2021
Ideal exit: 20 Jun 2022 (T+270) €9,907 3,000 shares @ €3.3023 0.0069% mcap 5.9% of flow
Common Stock
SEC:0001140361-21-032248:0 · 23 Sept 2021
Ideal exit: 20 Jun 2022 (T+270) About FREEMAN KEVIN D Kevin D. Freeman is an executive at Galectin Therapeutics Inc.